Shawn C Pun1, Heather J Landau2, Elyn R Riedel3, Jonathan Jordan1, Anthony F Yu1, Hani Hassoun2, Carol L Chen1, Richard M Steingart1, Jennifer E Liu4. 1. Department of Medicine/Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical Center, New York, New York. 2. Department of Medicine/Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical Center, New York, New York. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical Center, New York, New York. 4. Department of Medicine/Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical Center, New York, New York. Electronic address: liuj1234@mskcc.org.
Abstract
BACKGROUND: Autologous hematopoietic cell transplantation (HCT) is a first-line therapy for prolonging survival in patients with light-chain (AL) amyloidosis. Cardiac involvement is the most important determinant of survival. However, patients with advanced cardiac involvement have often been excluded from HCT because of high risk for transplantation-related mortality and poor overall survival. Whether baseline left ventricular global longitudinal strain (GLS) can provide additional risk stratification and predict survival after HCT in this high-risk population remains unclear. The aim of this study was to evaluate the prognostic implication of baseline GLS and the added value of GLS beyond circulating cardiac biomarkers for risk stratification in patients with AL amyloidosis undergoing HCT. METHODS: Eighty-two patients with newly diagnosed AL amyloidosis who underwent upfront HCT between January 2007 and April 2014 were included in the study. Clinical, echocardiographic, and serum cardiac biomarker data were collected at baseline and 12 months following HCT. GLS measurements were performed using a vendor-independent offline system. The median follow-up time for survivors was 58 months. RESULTS: Sixty-four percent of patients were in biomarker-based Mayo stage II or III. GLS, brain natriuretic peptide, troponin, and mitral E/A ratio were identified as the strongest predictors of survival (P < .0001). Other predictors included sex, creatinine, free AL, wall thickness, and ejection fraction. Mayo stage was significantly associated with outcome, with 5-year survival of 93%, 72% and 31% in stage I, II, and III patients, respectively. GLS of 17% was identified as the value that best discriminated survivors from nonsurvivors, and the application of this cutoff value provided further mortality risk stratification within each Mayo stage. CONCLUSIONS: GLS is a strong predictor of survival in patients with AL amyloidosis undergoing HCT, potentially providing incremental value over serum cardiac biomarkers for risk stratification. GLS should be considered as a standard parameter along with serum cardiac biomarkers when evaluating eligibility for HCT or other investigational therapies.
BACKGROUND: Autologous hematopoietic cell transplantation (HCT) is a first-line therapy for prolonging survival in patients with light-chain (AL) amyloidosis. Cardiac involvement is the most important determinant of survival. However, patients with advanced cardiac involvement have often been excluded from HCT because of high risk for transplantation-related mortality and poor overall survival. Whether baseline left ventricular global longitudinal strain (GLS) can provide additional risk stratification and predict survival after HCT in this high-risk population remains unclear. The aim of this study was to evaluate the prognostic implication of baseline GLS and the added value of GLS beyond circulating cardiac biomarkers for risk stratification in patients with AL amyloidosis undergoing HCT. METHODS: Eighty-two patients with newly diagnosed AL amyloidosis who underwent upfront HCT between January 2007 and April 2014 were included in the study. Clinical, echocardiographic, and serum cardiac biomarker data were collected at baseline and 12 months following HCT. GLS measurements were performed using a vendor-independent offline system. The median follow-up time for survivors was 58 months. RESULTS: Sixty-four percent of patients were in biomarker-based Mayo stage II or III. GLS, brain natriuretic peptide, troponin, and mitral E/A ratio were identified as the strongest predictors of survival (P < .0001). Other predictors included sex, creatinine, free AL, wall thickness, and ejection fraction. Mayo stage was significantly associated with outcome, with 5-year survival of 93%, 72% and 31% in stage I, II, and III patients, respectively. GLS of 17% was identified as the value that best discriminated survivors from nonsurvivors, and the application of this cutoff value provided further mortality risk stratification within each Mayo stage. CONCLUSIONS: GLS is a strong predictor of survival in patients with AL amyloidosis undergoing HCT, potentially providing incremental value over serum cardiac biomarkers for risk stratification. GLS should be considered as a standard parameter along with serum cardiac biomarkers when evaluating eligibility for HCT or other investigational therapies.
Authors: Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe Journal: Blood Date: 2004-03-25 Impact factor: 22.113
Authors: Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner Journal: Blood Date: 2011-08-09 Impact factor: 22.113
Authors: Dermot Phelan; Patrick Collier; Paaladinesh Thavendiranathan; Zoran B Popović; Mazen Hanna; Juan Carlos Plana; Thomas H Marwick; James D Thomas Journal: Heart Date: 2012-08-03 Impact factor: 5.994
Authors: Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan Journal: JACC Cardiovasc Imaging Date: 2010-02
Authors: A L Klein; L K Hatle; D J Burstow; J B Seward; R A Kyle; K R Bailey; T F Luscher; M A Gertz; A J Tajik Journal: J Am Coll Cardiol Date: 1989-04 Impact factor: 24.094
Authors: Marianna Fontana; Silvia Pica; Patricia Reant; Amna Abdel-Gadir; Thomas A Treibel; Sanjay M Banypersad; Viviana Maestrini; William Barcella; Stefania Rosmini; Heerajnarain Bulluck; Rabya H Sayed; Ketna Patel; Shameem Mamhood; Chiara Bucciarelli-Ducci; Carol J Whelan; Anna S Herrey; Helen J Lachmann; Ashutosh D Wechalekar; Charlotte H Manisty; Eric B Schelbert; Peter Kellman; Julian D Gillmore; Philip N Hawkins; James C Moon Journal: Circulation Date: 2015-09-11 Impact factor: 29.690
Authors: Anders H Tennøe; Klaus Murbræch; Johanna C Andreassen; Håvard Fretheim; Øyvind Midtvedt; Torhild Garen; Håvard Dalen; Einar Gude; Arne Andreassen; Svend Aakhus; Øyvind Molberg; Anna-Maria Hoffmann-Vold Journal: ACR Open Rheumatol Date: 2019-05-31
Authors: Ali M Agha; Nicolas Palaskas; Amit R Patel; Jeanne DeCara; Purvi Parwani; Cezar Iliescu; Jean B Durand; Peter Kim; Saamir Hassan; Gregory Gladish; Hans C Lee; Gregory P Kaufman; Juan C Lopez-Mattei Journal: Front Cardiovasc Med Date: 2021-06-29
Authors: Ali M Agha; Purvi Parwani; Avirup Guha; Jean B Durand; Cezar A Iliescu; Saamir Hassan; Nicolas L Palaskas; Greg Gladish; Peter Y Kim; Juan Lopez-Mattei Journal: Open Heart Date: 2018-09-26